title: Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?
authors.forename: Denis
authors.initials: D
authors.lastname: Mulleman
authors.forename: Emilie
authors.initials: E
authors.lastname: Ducourau
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.forename: David
authors.initials: D
authors.lastname: Ternant
authors.forename: Hervé
authors.initials: H
authors.lastname: Watier
authors.forename: Philippe
authors.initials: P
authors.lastname: Goupille
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D018501:Antirheumatic Agents / Q000097:blood* / Q000276:immunology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D004361:Drug Tolerance; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha